MedPath

Modification of the Human Colon and Oral Microbiome by Allogenic HSCT

Conditions
HSCT
Human Microbiome
Registration Number
NCT03942159
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Brief Summary

Allogenic HSCT brings significant changes in biodiversity and composition of the gut microbiome through antibiotic usage, the mucosal damage due to the chemo- and radiotherapy toxicity; compromised oral nutritional intake and graft-versus-host disease with gut damage as the complication. Aim of the study is to investigate the composition of the microbiota in both recipient and nursing relative donor, reveal changes in biodiversity after HSCT via 3-time points V3V4 16S rRNA and NGS sequencing of the colon and oral swabs, 3-indoxyl-sulfate measurement in the urine.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
15
Inclusion Criteria
  • indications to alloHSCT
  • nursing healthy donors 3-55 y.o.
Exclusion Criteria
  • unable to give samples for the test
  • graft rejection
  • previous HSCT

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
beta-index dynamics60 days after HSCT

biodiversity (beta-index) dynamics between time points before and after HSCT

Secondary Outcome Measures
NameTimeMethod
ROC (receiver operating characteristic)-curve of NGS (new-generation sequence)60 days after HSCT

sensitivity of NGS as a method of biodiversity evaluation

Proportion of patients with microbial domination after HSCT60 days after HSCT

evaluation of the dynamics of the microbial domination between time points before and after HSCT

Shannon-index dynamics60 days after HSCT

biodiversity (Shannon-index - an information statistic index, which means it assumes all species are represented in a sample and that they are randomly sampled) dynamics between time points before and after HSCT

Trial Locations

Locations (1)

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology

🇷🇺

Moscow, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath